沙利度胺抗肿瘤治疗  

Anti-tumor therapy of thalidomide

作　　者：吴鑫 曲秀娟[1] 张凌云[1] Wu Xin;Qu Xiujuan;Zhang Lingyun(Department of Medical Oncolo-gy,First Hospital of China Medical University,Shenyang 110001,China)

机构地区：[1]中国医科大学附属第一医院肿瘤内科,沈阳110001

出　　处：《国际肿瘤学杂志》2018年第8期490-493,共4页Journal of International Oncology

基　　金：“重大新药创制”科技重大专项（2017ZX09304025）;沈阳市科技计划人口与健康专项（17-230-9-01）

摘　　要：研究发现沙利度胺因具有抑制血管生成、调节免疫等作用从而产生抗肿瘤活性，在靶向治疗耐药的非小细胞肺癌、去势抵抗性前列腺癌、结直肠癌、晚期肝癌及晚期胃癌的治疗中显示出一定的疗效。临床研究也发现其在改善肿瘤恶病质及化疗相关性恶心、呕吐等方面具有一定的应用价值。Studies have found that thalidomide has anti-tumor activity due to its inhibitory effect on angiogenesis and immunomodulation, which has been effectively used in targeted therapy resistant non-small cell lung cancer, castration-resistant prostate cancer, colorectal cancer, advanced hepatoearcinoma and advanced gastric cancer. Many clinical studies have also found that it has certain practical value in the aspects of improvement of cancer cachexia and chemotherapy-induced nausea and vomiting.

关 键 词：肿瘤 治疗应用 沙利度胺 

分 类 号：R730.5[医药卫生—肿瘤]